1. Home
  2. VTGN vs GRNQ Comparison

VTGN vs GRNQ Comparison

Compare VTGN & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.26

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

HOLD

Current Price

$1.36

Market Cap

29.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTGN
GRNQ
Founded
1998
2013
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
29.6M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
VTGN
GRNQ
Price
$0.26
$1.36
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$0.90
N/A
AVG Volume (30 Days)
4.0M
15.2K
Earning Date
06-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,673,997.00
Revenue This Year
$124.49
N/A
Revenue Next Year
$353.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.55
52 Week Low
$0.20
$1.21
52 Week High
$5.14
$3.18

Technical Indicators

Market Signals
Indicator
VTGN
GRNQ
Relative Strength Index (RSI) 32.41 37.10
Support Level $0.20 $1.30
Resistance Level $0.66 $1.81
Average True Range (ATR) 0.05 0.10
MACD -0.03 -0.00
Stochastic Oscillator 10.27 4.88

Price Performance

Historical Comparison
VTGN
GRNQ

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

Share on Social Networks: